Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults
S Frey, G Poland, S Percell, A Podda - Vaccine, 2003 - Elsevier
The adjuvanted influenza vaccine FLUAD™ is composed of subunit influenza antigens
combined with the MF59-adjuvant emulsion. The vaccine was developed primarily for use in …
combined with the MF59-adjuvant emulsion. The vaccine was developed primarily for use in …
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: Results from a dose-finding clinical trial in older adults
G Della Cioppa, U Nicolay, K Lindert… - Human vaccines & …, 2012 - Taylor & Francis
Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …
Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly
The influenza vaccination is known as the most effective method for preventing influenza
infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis) …
infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis) …
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three …
M Minutello, F Senatore, G Cecchinelli, M Bianchi… - Vaccine, 1999 - Elsevier
A clinical trial to evaluate the safety and tolerability of a new influenza adjuvanted vaccine
(FLUAD®, Chiron Vaccines), compared with a conventional non adjuvanted influenza …
(FLUAD®, Chiron Vaccines), compared with a conventional non adjuvanted influenza …
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
S De Donato, D Granoff, M Minutello, G Lecchi… - Vaccine, 1999 - Elsevier
Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUADTM) were
compared to those of a non adjuvanted subunit vaccine in elderly subjects during three …
compared to those of a non adjuvanted subunit vaccine in elderly subjects during three …
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
R Gasparini, T Pozzi, E Montomoli… - European journal of …, 2001 - Springer
Three-hundred and eight outpatient elderly subjects (≥ 65 years) were randomly assigned
to receive the MF59-adjuvanted influenza vaccine (FLUAD; n= 204) or a conventional …
to receive the MF59-adjuvanted influenza vaccine (FLUAD; n= 204) or a conventional …
A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis
A Banzhoff, P Nacci, A Podda - Gerontology, 2003 - karger.com
Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …
influenza infection than younger adults, but get less protection from conventional …
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and …
D Sindoni, V La Fauci, R Squeri… - Journal of preventive …, 2009 - europepmc.org
The objective of this study was to evaluate and compare the safety, tolerability and
immunogenicity for two seasonal influenza subunit vaccines, one with MF59 adjuvant …
immunogenicity for two seasonal influenza subunit vaccines, one with MF59 adjuvant …
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
R Li, H Fang, Y Li, Y Liu, M Pellegrini, A Podda - Immunity & Ageing, 2008 - Springer
Background The safety and immunogenicity of an MF59™-adjuvanted subunit influenza
vaccine (Sub/MF59™; FLUAD®, Novartis Vaccines) was evaluated among elderly Chinese …
vaccine (Sub/MF59™; FLUAD®, Novartis Vaccines) was evaluated among elderly Chinese …
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly …
C Hatz, F von Sonnenburg, D Casula, M Lattanzi… - Vaccine, 2012 - Elsevier
BACKGROUND: Vaccines against pandemic A/H1N1 influenza are required to protect the
entire population. This dose range study aimed to identify priming antigen and adjuvant …
entire population. This dose range study aimed to identify priming antigen and adjuvant …